Novel antiseptic formulation for the treatment of blepharitis


Veloce BioPharma is clinical stage company that has successfully completed multiple phase 2 clinical trials in dermatology for indications that include molluscum contagiosum, chemotherapy associated paronychia, and common warts with our novel antiseptic formulation. As company founders are ophthalmologists, and diseases of the eyelid and ocular surface crossover with the field of dermatology- it is a natural fit for our company to build an ophthalmology division. Our ocular drug candidate is 505 (b)2 pathway enabled and ready for phase 2 testing after the submission of an IND with the FDA.

Project Team

Jesse  Pelletier MD FACS
Jesse Pelletier MD FACS

Project Status

Clinical Stage
Clinical Trials
Patent Status
Patent not filed

Funding Opportunity

Opportunity type
Funding requested
Funding allocated


Our founders have been involved with the chemistry of PVI for decades. Our CEO, successfully developed and sold ($300M) a PVI based formulation for the treatment of adenoviral conjunctivitis. Based on this success and a multitude of scientific publications, we believe that our novel formulation through mechanisms of penetration enhancement along with properly titrated amounts of free iodine reaching target tissues will be an effective treatment for blepharitis.

Project Details

Our current hypothesis is that this formulation is a safe and effective treatment for blepharitis. Because of the long history and efficacy of our API, we are able to pursue FDA approval through the 505 (b)2 pathway. Our project will consist of two phases- the first will be the submission of the IND to the FDA. Once this is completed, we will commence Phase 2 clinical trials through the aforementioned pathway. The Phase 2 clinical trial will enroll approximately 50-100 patients in a placebo-controlled, randomized clinical trial to be conducted in the US. Primary endpoints will include global assessment scores of eyelid erythema, edema, lash debris, lash follicles, palpebral conjunctiva, and meibomian glands. Secondary endpoints will include assessment of psychometrics and microbiological parameters.

Project Timeline

  • Novel antiseptic formulation for the treatment of blepharitis

    Required Funding$5,000,000
    Duration18 Months

    as above